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Although gain of oncogene functions and loss of
tumor suppressor functions are driving forces in
tumor development, the tumor microenvironment,
comprising the extracellular matrix, surrounding
stroma, signaling molecules and infiltrating immune
and other cell populations, is now also recognized as
crucial to tumor development and metastasis. Many
interactions at the tumor cell-environment interface
occur at the protein level. Proteomic approaches are
contributing to the definition of the protein
constituents of the microenvironment and their
sources, modifications, interactions and turnover, as
well as providing information on how these features
relate to tumor development and progression.
Recently, proteomic studies have revealed how cancer
cells modulate the microenvironment through their
secreted proteins and how they can alter their protein
constituents to adapt to the microenvironment.
Moreover, the release of proteins from the
microenvironment into the circulatory system has
relevance for the development of blood-based cancer
diagnostics. Here, we review how proteomic
approaches are being applied to studies of the tumor
microenvironment to decipher tumor-stroma
interactions and to elucidate the role of host cells in
the tumor microenvironment.* Correspondence: shanash@mdanderson.org
1Anderson Cancer Center, Bertner Avenue, Houston, TX 77030, USA
Full list of author information is available at the end of the article
© 2014 Hanash and Schliekelman; licensee Bio
any medium, for 12 months following its pub
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe tumor microenvironment
The tumor microenvironment is functionally important
for tumor development and progression. It comprises
multiple components: the extracellular matrix (ECM),
surrounding stromal cells and infiltrating cells, and sig-
naling molecules (Figure 1). Studies of the tumor
microenvironment have involved model systems, both
in vitro and in vivo, and the use of patient samples.
The stroma, ECM and infiltrating cells interact with
tumor cells, and have the capacity to both aid and
hinder tumor development. The ECM is a structural
network composed primarily of collagens, laminins and
various glycoproteins. It serves a scaffolding function
for tissue organization, in part through its physical
properties but also by interacting with cells through
cellular receptors and embedded signaling molecules
[1,2]. Increased matrix stiffness enhances tumor-cell
migration in many tumor types [3-5]. Interactions be-
tween integrins on the cell surface and matrix proteins
provide signaling information that affects tumor cell
proliferation, motility and other functions [6]. In
addition to the structural ECM components, matricel-
lular proteins that are largely produced by cancer-
associated fibroblasts (CAFs) have dual roles as struc-
tural and signaling factors [7,8]. The stroma can be
composed of a wide variety of cell types, including
resident epithelial cells, fibroblasts, endothelial cells,
pericytes and cells of the immune system [9,10]. Fibro-
blasts are primarily responsible for ECM production
and participate in the wound-healing process [11].
Endothelial cells support vascular development and are
essential for angiogenesis, which is also required for
tumor growth. The majority of solid tumors are infil-
trated with inflammatory cells, suggesting a host im-
mune response to the tumor. Nevertheless, immune
cells frequently fail to respond adequately to the tumor
and are subverted to aid in tumor development.Med Central Ltd. The licensee has exclusive rights to distribute this article, in
lication. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and











Figure 1 Constituents of the tumor microenvironment. A mix of
tumor cells, cancer-associated fibroblasts and inflammatory or immune
cells permeate the microenvironment. These cells produce the
extracellular matrix and an assortment of soluble factors. Cross-talk
between the resident cell populations is further contributed to by the
release and/or uptake of exosomes and microvesicles loaded with
cargo that includes nucleic acids, proteins and metabolites.
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the tumor microenvironment has dual capacities to in-
duce either a beneficial or an adverse effect on tumori-
genesis. Recently, therapies have been developed that
target tumor cells for destruction by the host immune
system [12]. In this review, we discuss proteomic ap-
proaches that are being applied to studies of the tumor
microenvironment in order to decipher tumor-stroma
interactions and to elucidate the role of host cells in the
microenvironment. We also discuss potential biomarker
applications of proteins that are derived from tumor-
microenvironment interactions.The reach of proteomics
Advances in protein analysis by mass spectrometry
(MS), coupled with front-end separations and peptide or
protein labeling, have allowed comprehensive analysis of
the protein complement of a cell, tissue or organ [13].
Proteins from whole-cell lysates, from particular cell-
derived compartments such as exosomes [14], or from
chromatographic or affinity-capture fractions (Figure 2)
are subjected to enzymatic cleavage into peptides,
followed by chromatographic separation and MS analysis
(Figure 3a). Techniques for proteome analysis utilizing
electrospray ionization (ESI) or matrix-assisted laser de-
sorption ionization (MALDI) have advanced substan-
tially [15]. With tandem MS analysis (MS/MS), an initial
determination of the mass of a peptide is made (MS1)
and a subsequent MS analysis (MS2) measures peptide
fragments and provides accurate sequence information
by matching to sequence databases. Biological samples
have a high degree of complexity and protein concentra-
tions vary across a wide dynamic range, complicating
proteomic analysis [16]. To reduce complexity, samples
can be fractionated or enriched in particular compart-
ments prior to MS analysis [17]. MS may be combined
with activity-based probes to determine not only the oc-
currence and quantification of proteins but also their
functional activity [18].
Affinity-based proteomics involving capture agents,
notably antibodies, can be utilized to facilitate high-
throughput analysis of proteins or for confirmatory stud-
ies, for example, using tissue microarrays (Figure 3b)
[19]. Antibodies may be spotted onto an array to allow
capture and identification of their targets. Alternatively,
with reverse-phase protein arrays, lysate samples are
spotted onto arrays that are incubated with an antibody
against a known target [20]. Proteins and peptides may
also be spotted onto microarrays for their interrogation.
The depth of analysis currently achievable through
proteomics is such that, given a sufficient number of
cells, a protein product of virtually any expressed gene
in a cell population should be identifiable. The challenge
for proteomic studies of the tumor microenvironment
stems from the cellular complexity of the microenviron-
ment, necessitating separate analysis of individual cell
types. Moreover, the insoluble nature of the matrix com-
plicates analysis of intact proteins, a challenge that can
be overcome by first digesting the matrix before MS of
the resulting peptide mixture. MS tools are increasingly
being utilized to characterize the numerous post-
translational protein modifications that play a role in the
tumor microenvironment - for example, through their
impact on the cross-linking of matrix proteins [21].
Above all, for studies of the tumor microenvironment to
be most informative, they must utilize the in-depth,




















Figure 2 Analysis of the proteome of cell populations by sub-compartment. Proteomics is particularly informative when applied to
individual cellular compartments, such as the cell surface, secretome, the nucleus or other organelles, for which isolation and analysis procedures
are required. Moreover, aside from the identification of constituent proteins, there is a need to assess post-translational modifications (PTMs) of
proteins, including major modifications such as phosphorylation and glycosylation, in addition to cleavage and proteolysis. Cell surface proteins
(for example, receptors and antigens) may be captured through the use of lipid impermeable biotin followed by capture of surface proteins using
monomeric avidin and subsequent mass spectrometry (MS) analysis. Proteins in cell culture media may be fractionated as intact proteins using
chromatography followed by digestion of individual fractions and MS analysis. Alternatively, particulate material (for example, exosomes) may be
first isolated from media, followed by their MS analysis separately from the soluble fraction in the media.
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and centers.
Insights from proteomic profiling of the tumor
extracellular matrix
The ECM regulates intercellular communication and
serves as a repository for cell signaling molecules, in
addition to serving a structural scaffolding role for cells
[22]. Proteomics has provided insights into constituents
of the ECM and their regulation (Table 1). One ap-
proach involves stable isotope labeling of amino acids in
cell culture (SILAC), which enables proteins that are
newly produced by cells to be differentiated from culture
media supplemented with serum [23]. Studies analyzing
the proteins released from cell lines have defined ECM
constituents that are produced by tumor cells. Com-
bined liquid chromatography-tandem MS (LC-MS/MS)
has been used to analyze proteins released into condi-
tioned media, surface proteins and whole-cell lysates of
murine lung cancer cells that have undergone epithelial-
mesenchymal transition (EMT, a process that allows
tumor cells with an epithelial phenotype to convert to
mesenchymal cells). These analyses revealed increasedexpression of a number of ECM proteins that indicate
that the tumor cells are shaping their microenvironment,
including: fibronectin, which binds to integrin receptors;
a member of the collagen family, collagen 6A1; and
members of the laminin family of glycoproteins, lami-
nins A5, B2, and C1 [24].
Runt-related transcription factor 2 (RUNX2) is posi-
tively associated with tumor progression in prostate can-
cer [25]. LC-MS/MS analysis of secreted proteins that
are upregulated after RUNX2 overexpression in prostate
cancer cells revealed increased expression of a number
of proteins, including basement membrane components
laminins A5 and B1 [25]. A shotgun proteomic analysis
of metastatic melanoma cell-line secretomes also identi-
fied the matrix proteins fibronectin and extracellular
matrix protein 1, as well as the matricellular proteins
SPARC (secreted protein, acidic, cysteine rich) and
osteopontin [26]. Studies in which EMT was induced in
Madin-Darby canine kidney cells by H-RAS demon-
strated both extracellular remodeling and decreased ex-
pression of basement membrane proteins, as well as
increased expression of fibronectin, biglycan and SPARC


















(a) (b) Antibody array
Reverse-phase protein array
Protein Antibody
Figure 3 Methodologies for proteomic analysis. (a) Experimental workflow of common mass spectrometry (MS)-based proteomic approaches.
Proteins from particular compartments or from whole-cell lysates may be separated using gel electrophoresis or chromatography. Individual
fractions are subsequently digested, followed by MS of peptide mixtures. (b) Affinity-based proteomic analysis is generally applied to intact
proteins. Antibodies with defined specificities may be arrayed on a glass slide or membrane followed by incubation with a lysate. Alternatively,
with reverse phase protein arrays, lysates are spotted and incubated with individual antibodies that target a specific protein.
Hanash and Schliekelman Genome Medicine 2014, 6:12 Page 4 of 12
http://genomemedicine.com/content/6/2/12changes in ECM proteins during the development of he-
patocellular carcinoma. They observed upregulation of
collagen type IV, VI, VII, X, XIV, XV, XVI, and XVII, of
splice variants Col4a2, Col6a2, and Col6a3 and of nido-
gen 1, decorin, and perlecan, among other proteins, indi-
cating the utility of ECM profiling for hepatocellular
carcinoma classification and diagnosis. When compared
to enchondromas, chondrosarcomas have been found to
possess high levels of the carboxy-terminal pro-peptide
of collagen 1A1 (PC1CP) and low levels of the carboxy-
terminal pro-peptide of collagen 2A1 (PC2CP), as deter-
mined by proteomic analysis [30]. Immobilized PC2CP
increased the apoptosis of primary human chondrocytes,
whereas soluble PC2CP led to increased cellular migra-
tion. Furthermore, soluble PC2CP increased the expres-
sion of genes that are known to favor tumor
progression, such as VEGF (encoding vascular endothe-
lial growth factor) and CXCR4 (encoding chemokine re-
ceptor CXCR4), demonstrating the critical importance
of protein localization in cancer [30].
Other studies assessed ECM regulation through ana-
lysis of post-translational modifications and matrix
cross-linking. Upregulation of PLOD2 (procollagen-
lysine, 2-oxoglutarate 5-dioxygenase 2), a regulator of
collagen stiffness, in combination with COL6A1 was
found to promote bone metastasis [31]. Transglutaminase
2, a crosslinker of ECM components, was upregulated ininvasive ovarian cancer cell lines [32]. The upregulation of
collagen-binding proteins, notably CD44 and integrins A1,
B1 and gamma3, in these invasive cell lines provided
insight into how cancer cells can alter their surface re-
ceptors to adapt to the microenvironment. Matrix stiff-
ness regulates cell behavior, and a SILAC-based study of
changes in protein synthesis in cells grown on rigid or
soft matrix found increased synthesis of cytoskeletal and
glycolysis proteins by those cells grown on rigid surfaces
[33]. Chen et al. [34] assessed phosphorylation of pro-
teins during cell attachment to collagen by LC-MS/MS
analysis of SILAC-labeled HeLa cells. They found that
357 proteins were differentially phosphorylated, and
among these were cytoskeleton-related proteins (54
proteins), transcriptional regulators (52 proteins) and
kinases or phosphatases (33 proteins). Knockdown of
nine kinases and phosphatases significantly reduced
cell migration. Moreover, knockdown of four of these
proteins - activator of S-phase kinase (DBF4), G-protein
coupled receptor kinase 6 (GRK6), p21 protein (Cdc42/
Rac)-activated kinase 2 (PAK2), and focal adhesion
kinase (FAK/PTK2) - also resulted in decreased inva-
sion. Blocking of phosphorylation by mutation of the
serine or threonine residues in DBF4, GRK6 or PAK2
also inhibited collagen I binding, migration and inva-
sion, demonstrating that integrin-dependent phosphor-
ylation regulates these proteins [34].
Table 1 Highlights from proteomic studies of the tumor microenvironment
Experimental system Approach Key proteins
Tumor ECM EMT in murine cancer cells [24] MS of subcellular
fractions
Fibronectin, collagens, laminins
Metastatic melanoma cells [26] Secretome MS Fibronectin, ECM1, SPARC, osteopontin
Hepatocarcinogenesis [29] ECM MS Collagen splice variants, nidogen, decorin,
perlecan
Cell attachment to collagen [34] Phosphoprotein
analysis
DBF4, GRK6, PAK2, FAK/ PTK2
Breast cancer metastasis [34] MS Cystatin-M
Tumor invasiveness [41] Antibody libraries hsp90α
Tumor-stroma interactions Tumor versus normal stroma [45] Laser capture + MS CapG (actin-regulating protein)
CAFs [49] MS of cell lysates Caveolin-1
MMP7 effect of CAFs [50] MS of cell lysates IGFBP5
Lung cancer TME [54] Cytokine assays CXCL1, IL-18
Stromal cell secretome [60] Antibody arrays HGF
Immune cells in the tumor
microenvironment
Mesothelioma effusions [67] Antibody arrays HGF, MIP-1d, MIP-3a, NAP-2
Ovarian tumor macrophages [68] MS of supernatants 14-3-3 zeta
CD45RA + versus CD45RO + T
cells [70]
MS of cell lysates Cell redox proteins
MDSCs + IL1B [72] MS of cell lysates FAS pathway and caspase network
Some studies have focused on the ECM, others on tumor-stroma interactions and on immune cells infiltrating the tumor microenvironment. These studies have
utilized various experimental systems applied to different tumor types. Some of the key proteins that have been found to be involved are highlighted, illustrating the
numerous protein families that play a role in the tumor microenvironment. Abbreviations: CXCL1, interferon-inducible protein-1; DBF4, activator of S-phase kinase 4;
GRK6, G-protein coupled receptor kinase 6; FAK, focal adhesion kinase; hsp90α, heat shock protein 90α; IGFBP5, insulin growth factor binding protein 5; IL-18,
interleukin-18; IL1B, interleukin1B; MIP-1d, macrophage inflammatory protein-1d; MIP-3a, macrophage inflammatory protein-3a; MMP7, matrix metalloproteinase 7;
NAP-2, neutrophil-activating peptide-2; PAK2, SPARC, secreted protein, acidic, cysteine rich; TME, tumor microenvironment.
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play a role in remodeling ECM and contribute to ECM
composition. In a screen for proteins related to breast
cancer metastasis to bone tissue, an inhibitor of several
cathepsin proteases, cystatin-M (CST6), was observed to
be downregulated [35]. Ectopic expression of CST6 sup-
pressed metastasis in animal studies, whereas CST6
knockdown increased tumor aggressiveness [35]. Work
by Blanco et al. [31] highlighted the interplay of ECM
modulators consisting of the protease inhibitors CST1,
CST2, and CST4 and the plasminogen-activating prote-
ases PLAT and PLAU. The imbalance between matrix
metalloproteinases (MMPs) and the tissue inhibitors of
metalloproteinases (TIMPs) has been widely investigated
[36]. Several studies have used proteomics to identify
targets of membrane type 1 metalloprotease (MT1-
MMP), which has been proposed to play an important
role in cell invasion [37,38]. Affinity purification of
MT1-MMP identified 163 proteins associated with
MT1-MMP through LC-MS/MS analysis [39]. Nine
membrane proteins were confirmed to be cleaved by
MT1-MMP by co-expression, including the Lutheran
blood group glycoprotein (Lu). Tam et al. [40] identified
new targets of MT1-MMP through an LC-MS/MS
screen of isotope-labeled proteins from a breast cancercell line, confirming the substrates with MALDI.
Interleukin-8 (IL-8) was shown to be processed by MT1-
MMP to a more active form, whereas fibronectin expres-
sion was increased after MT1-MMP transfection. A
novel proteomic approach, using fluorophore-assisted
light inactivation (FALI) with antibody libraries for the
identification of proteins related to invasiveness, revealed
an extracellular form of hsp90α that acts as a chaperone
for MMP2 and assists in its invasion-associated activa-
tion [41]. A comparison of high- and low-invasive ovar-
ian cell lines confirmed that only cell lines expressing
MT1-MMP were invasive through collagen-binding [41].
A targeted approach using the TRAMP (transgenic
adenocarcinoma of the mouse prostate) mouse model
found a general increase in the expression of ECM-
modifying proteases, such as MMPs and cysteine prote-
ases, during tumor progression [42]. Raf/MEK/ERK sig-
naling disrupts tissue polarity in breast epithelial cells
through MMP9 activity [43]. LC-MS/MS analysis of
conditioned media from cells with or without active
MMP9 demonstrated that the basement membrane
component laminin 111 is a target of MMP9 [43]. It
should be noted that proteins may be released into the
microenvironment via many mechanisms. There is cur-
rently substantial interest in the role of micro-particles
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extracellular messengers whose protein content can be
readily profiled by MS [14].
These studies are illustrative of the contribution of
proteomic analysis to elucidating how tumor cells mod-
ify their microenvironment through the production of a
diverse set of extracellular matrix proteins and proteases.
A potential limitation of these studies is, however, that
they do not address in a mechanistic way how the di-
verse mutations and genomic alterations observed in
tumor cells, either singly or in combination, contribute
to the capacity of these cells to alter their microenviron-
ment. Thus, the extent to which various oncogenic
drivers impact the tumor microenvironment through
common or vastly distinct processes remains to be
determined.
Deciphering tumor-stroma interactions
Proteomics has provided insight into the role of CAFs
and other stromal cells in tumor development (Table 1).
A proteomic analysis of de-cellularized matrix from tu-
mors with marked angiogenesis identified 50 angiogenic
proteins. One such protein, galectin-1, was demon-
strated to act in endothelial cell recruitment [44]. A
proteomic comparison of laser capture microscopy-
dissected stroma from nasopharyngeal carcinoma tu-
mors with normal stroma identified 60 differentially
expressed proteins in the tumor stroma, including the
actin-regulating protein CapG, which was upregulated
[45]. Reverse-phase protein microarrays targeted at sig-
naling proteins were used to compare tumor epithelia,
normal epithelia, tumor stroma and normal stroma.
Interestingly, the tumor epithelia and stroma bore more
similarity to each other than to normal epithelia or
stroma, respectively, suggesting that EMT occurred in
the epithelial tumor tissue. In particular, proteins related
to the mitogen-activated protein kinase 1 (MAPK 1)
pathway were more abundant in the tumor stroma and
epithelia [46]. Fleming et al. [47] compared the mam-
mary microenvironment of premenopausal African-
American (AA) women and Caucasian-American (CAU)
women, and found that the breast microenvironment in
AA women was more restrictive of tumor growth. An
LC-MS/MS analysis of ECM from AA and CAU women
revealed differences in ECM composition (only 50%
overlap of ECM proteins) and identified upregulation of
actin cytoskeleton signaling in the ECM of AA women.
A novel LC-MS/MS analysis also measured active hor-
mones in the breast tissue directly, revealing higher
levels of estradiol, estriol and 2-methoxyestrone in
breast tissue from CAU women [47].
CAFs also contribute to the tumor microenvironment.
Activated pancreatic stellate cells (PSC) promote tumor
implantation, and conditioned media from PSCsenhance invasion and proliferation of cancer cells. An
analysis comparing quiescent and activated PSCs found
a large increase in protein secretion by the activated
cells. The secreted proteins had 60% overlap with pro-
teins from cancer cell line secretions and played a role
in wound healing, inflammation, ECM and fibrosis [48].
Work by Trimmer et al. [49] identified loss of caveolin-1
(CAV-1) in CAFs as a predictor of clinical outcome,
probably resulting from autophagy of CAFs with CAV-1.
A proteomic analysis of CAV-1-deficient fibroblasts sup-
ported this hypothesis by showing upregulation of pro-
teins related to oxidative stress. Superoxide dismutase 2
(SOD2) was identified as a suppressor of this effect by
reducing oxidative stress [49].
A proteomic analysis comparing MMP7-treated and
untreated colonic fibroblasts identified Insulin growth
factor binding protein-5 (IGFBP-5) as a substrate of
MMP7 activity [50]. MMP-7 acts as a stimulating factor
in the proliferation and migration of colonic myofibro-
blasts through blockade of IGFBP-5 inhibition of IGF-II
[50]. An MS analysis of PTEN (phosphatase and tensin
homolog)-null stromal cells expressing the microRNA
miR-320 revealed altered secretome expression of pro-
teins such as MMP9, MMP2, bone morphogenic protein
1 (BMP1), lysyl oxidase-like 2 (LOXL2) and EMILIN2
when compared to a control [51]. Confirmatory studies
demonstrated that blocking of MMP9 and EMILIN2 re-
duced the ability of conditioned media to promote the
migration of epithelial cancer cells or to recruit endothe-
lial cells, respectively. Furthermore, the secretome signa-
ture also correlated with patient outcome [51]. Newman
et al. [52] identified factors secreted from fibroblasts
that support endothelial cell lumen formation. PCOLCE,
Col1A1, transforming growth factor β-inducible gene
H3 (βIG-H3), SPARC, or IGFBP7 were identified in
fibroblast-conditioned media fractions that were neces-
sary for endothelial cell lumen formation [52]. Knock-
down of combinations of these factors in fibroblasts
inhibited endothelial cell lumen formation [52]. While
stromal cells affect tumor cell behavior, there are recip-
rocal interactions. CAFs and tumor-adjacent fibroblasts
(TAFs) in the microenvironment of breast cancer cells
display features similar to those of tumor cells. CAFs
and TAFs can be distinguished from normal breast fi-
broblasts on the basis of their proteome [53].
The co-culture of fibroblasts and cancer cells enables
direct interactions to be studied. Co-culture of a murine
K-ras mutant lung adenocarcinoma cell line (LKR-13)
with murine lung stromal cells enhanced the migration
and increased the proliferation of LKR-13 cells; co-
culture also induced these cells to form epithelial tubes
[54]. An LC-MS/MS analysis revealed loss of cell adhe-
sion proteins such as E-cadherin and provided evidence
of EMT in the cancer cell line when grown with
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by a multiplexed cytokine assay to identify signaling
molecules at concentrations below the limit of detection
of MS. Chemokine CXCL1 and IL-18 were found to be
necessary for increased proliferation and migration [54].
Conditioned media from gastric cancer-associated myo-
fibroblasts increased cancer cell proliferation, migration
and invasion in a cancer cell line [55]. An LC-MS/MS
analysis of isobaric tagged cells identified downregula-
tion of βIG-H3 in CAFs compared to normal or adjacent
myofibroblasts. βIG-H3 inhibited IGF-II-stimulated mi-
gration and proliferation of cancer cells [55].
Co-culture with stromal cells has also been shown to
increase resistance to anti-cancer therapies in many can-
cer cell lines [56-59]. Conditioned media from some
stromal lines were found to be capable of rescuing the
growth of melanoma cell lines that were exposed to the
Raf inhibitor vemurafenib [60]. Antibody array analysis
of secreted factors, comparing media from stromal cell
lines that were or were not shown to be capable of res-
cuing melanoma cells from vemurafenib treatment, re-
vealed a potential role for hepatocyte growth factor
(HGF), mediated through the MAPK and PI3K-AKT
pathways, in resistance to vemurafenib. Head and neck
squamous cell carcinoma cells and fibroblasts produce
more prostaglandin PGE2 when co-cultured [61]. More-
over, co-culture of colon cancer cells with normal colon
fibroblasts produced a desmoplastic set of proteins
expressed solely in the co-culture but not in the individ-
ual cultures. Secreted proteins in this set included colla-
gen type XII, a marker of the invasive front of colorectal
tumors [62]. These and other studies that were based on
the well-established finding that stromal cells modify the
behavior of tumor cells and vice versa have elucidated
signaling molecules, proteases and other proteins that
are crucial to this interaction. The challenge is to iden-
tify the most critical factors that might be targeted by
small molecule or antibody therapeutics.
Elucidating the role of immune cells in the
microenvironment through proteomics
There is intense interest in elucidating critical interac-
tions between tumor cells and immune cells in the
microenvironment. Cells with immunosuppressive po-
tential include macrophages, regulatory T (Treg) cells
and myeloid derived suppressor cells (MDSCs). Infiltrat-
ing immune cells are capable of stimulating tumor
growth through the expression of signaling molecules
(such as interleukins or cytokines) and growth factors
(such as epidermal growth factor (EGF), TGFβ and
fibroblast growth factor (FGF)), as well as through the
secretion of ECM-modifying proteases [63-66]. Both
antibody arrays and MS have been utilized to profile im-
mune cells and their derived cytokines (Table 1). Anantibody array was used to analyze the expression of cy-
tokines in mesothelioma pleural effusions and in condi-
tioned media from cell lines established from the same
tumors. This study detected HGF, macrophage inflam-
matory protein (MIP)-1d, MIP-3a, neutrophil-activating
peptide (NAP)-2, and pulmonary activation-regulated
chemokine (PARC) exclusively in the pleural effusions,
suggesting that these cytokines may be primarily
expressed by stromal or inflammatory cells [67]. Immu-
nohistochemistry revealed infiltration of macrophages,
NK cells and T-lymphocytes in the mesothelioma tu-
mors. Mesothelioma cell lines expressed many chemo-
kines that seem to recruit immune cells, such as
interferon-inducible protein-10 (CXCL10), macrophage
migration inhibitory factor (MIF), monocyte chemo-
attractant protein-1 (MCP-1, also known as CCL2), epi-
thelial neutrophil-activating protein-78 (ENA-78), MIP-
1b, IL-8, growth regulatory protein (GRO) and RANTES
[67]. An LC-MS/MS analysis of the cell supernatants
from tumor-associated monocytes or macrophages iso-
lated from the ascites of ovarian cancer patients identi-
fied 14-3-3 zeta, an adapter protein that potentially
regulates a large number of molecules in signaling path-
ways [68].
Oxidative stress promotes the infiltration of inflamma-
tory cells by providing favorable growth conditions, and
these cells further contribute to the hypoxic environ-
ment by producing reactive oxygen species (ROS) [69].
A comparative proteome analysis of naive CD45RA+T
cells and their memory/effector CD45RO+T cells in re-
sponse to oxidative stress identified differential expres-
sion of proteins that are involved in signaling pathways,
in regulating the cellular redox status and in maintaining
structural cell integrity, providing a basis for therapeutic
interventions to overcome oxidative stress in the tumor
microenvironment [70].
MDSCs regulate immunosuppression during tumor
development and cancer-associated inflammation in-
creases the accumulation of MDSCs [71]. A proteomic
analysis of MDSCs treated with IL-1B to induce inflam-
mation identified the upregulation of the FAS pathway
and caspase network [72]. Furthermore, a follow-up
study revealed that inflammation reduces Fas-mediated
apoptosis in MDSCs [72]. Igγ-1 chain C region (IGHG1)
was uniquely identified in pancreatic cancer tissue by an
LC-MS/MS analysis comparing this tissue with normal
pancreatic tissue. A cell line expressing IGHG1 on its
surface was generated, and when injected into a mouse
pancreatic tumor model, resulted in tumors that grew
more quickly than in controls, and these mice had
shorter survival times. The mechanism of the increased
rate of tumor growth appeared to be related to immuno-
suppression, as NK cells were less cytotoxic to pancre-
atic cancer cells that expressed IGHG1 [73]. Clearly,
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and progression through the secretion of cytokines and
ECM components, and they can also help to promote a
hypoxic environment.
The above studies notwithstanding, there remains a
substantial need and opportunity for in-depth profiling
of immune infiltrating cells and cancer cells to define
their expression patterns in specific compartments (for
example, in the secretome and at the cell surface) and to
explore how the expression repertoire in each compart-
ment might contribute to enhancing or suppressing tumor
development and progression. Such understanding is
likely to expand the repertoire of therapeutic targets for
immunotherapy. Moreover, the role of post-translational
modifications and their impact on the interactions be-
tween cancer cells and immune cells needs to be further
explored. Besides proteomic analysis, deciphering the me-
tabolome in the tumor microenvironment and determin-
ing how cancer cells may metabolically inhibit immune
cells, allowing tumor development and cancer progres-
sion, are likely to be highly informative and complemen-
tary to proteomic profiling.
Profiling of signaling proteins and pathways
The presence of diverse cytokines, chemokines and
growth factors affects the behavior of both malignant
and stromal cells. Nevertheless, elucidation of how a
multitude of factors act in concert remains a challenge.
Most studies have identified important roles for particu-
lar factors in a given setting. For example, conditioned
media from glioblastoma multiforme (GBM) cells can
transform neural precursor cells, causing them to be-
come highly proliferative and to express markers of stem
cells. LC-MS/MS analysis of GBM-conditioned media
identified chitinase-3-like protein 1 (CHI3L1, also
known as YKL40) and histone H2A-X, along with VEGF,
EGF and platelet-derived growth factor (PDGF) [74].
The relevance of these factors in a broader setting re-
mains to be determined. Likewise, Fukaya et al. [75] re-
ported the identification of a secreted factor from
neuroblastoma cells that stimulates IL-6 production in
bone marrow stromal cells. Fractionation and LC-MS/
MS analysis of conditioned media identified galectin-3-
binding protein as the stimulating factor [75]. Condi-
tioned media from estradiol-stimulated prostate stromal
cells promote the migration of prostate cancer cells [76].
Through a MALDI-TOF analysis of conditioned media,
secreted enolase 1 (ENO1) was identified and shown to
be the factor responsible for increased cell migration,
acting at the surface of prostate cancer cells to promote
plasminogen activation [76]. An analysis of mammary
fat tissue by MS and antibody arrays identified a large
number of cytokines and growth factors expressed by
adipocytes [77]. A broad exploration of cytokines wasconducted in fluid collected from surgical wounds of
breast cancer patients before and after targeted intraop-
erative radiotherapy treatment (TARGIT) [78]. Wound
fluid from TARGIT-treated patients was less stimulatory
to migration and proliferation than that from untreated
patients. Cytokine analysis using an antibody array re-
vealed reduced levels of HGF, leptin, RANTES, IL-6, IL-
7, IL-8 and IL-10, while FAS, FGF-4, IL-4, IL-5, and IL-
13 were upregulated [78].
From the microenvironment to the circulation:
the search for biomarkers
The microenvironment is a potentially rich source of
biomarkers that are released into the circulatory system
and can be mined through proteomics. Cohen et al. [79]
performed an LC-MS/MS analysis of plasma from breast
cancer patients and identified fibronectin, clusterin, gel-
solin and protein AMBP (alpha-1-microglobulin/inter-α-
trypsin inhibitor light chain precursor) as differentially
expressed between infiltrating ductal and invasive breast
cancers. Vitronectin was identified in an MS analysis
comparing serum from breast ductal carcinoma in situ
(DCIS) patients to healthy controls. Immunohistochem-
istry analysis of tumors and adjacent tissue revealed high
expression of vitronectin in the ECM of the stroma [80].
MALDI-MS identified IGHA2 as a biomarker of micro-
environment remodeling by breast tumors [81]. Elevated
levels of tumor microenvironment-derived proteins in
the circulation have been shown to have diagnostic po-
tential for pancreatic cancer [82]. A proteomic analysis
of plasma from mice with HER2/neu-induced mammary
tumors and plasma from control mice with inflamma-
tion was performed to determine the repertoire of
changes in the plasma proteome during breast tumor
development. In this study, 20% of proteins that were
upregulated upon tumor onset were considered likely to
be associated with a tumor-specific host response, in-
cluding multiple macrophage signaling proteins, TAM-
related proteases, and ECM proteins [83]. Altered glyco-
sylation of the ECM-modifying protease plasminogen
was found in gastric cancer precursor lesions, suggesting
its potential as a biomarker [84]. LC-MS/MS analysis of
conditioned media from primary neurofibroma Schwann
cells compared to Schwann cells from normal nerve tis-
sue identified a secreted form of retinoic acid responder
1 (RARRES1) from neurofibroma Schwann cells [85].
Associations have been made between the expression
of protein biomarkers identified in proteomic studies
and patient prognosis. Laser-capture microdissection
was used to assess proteomic changes in the stroma of
nasopharyngeal carcinoma, resulting in the identification
of periostin as a protein that is upregulated in these car-
cinoma cells when compared to normal nasopharyngeal
tissue. Overexpression of periostin in nasopharyngeal
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advanced clinical stage [86]. In another study, expression
of galectin-1 (Gal-1) in the tumor microenvironment
(near non-tumor tissues) was associated with poor sur-
vival in classic Hodgkin lymphoma (cHL) patients [87].
Tissue interstitial fluid (TIF) from tumors also repre-
sents a potential source for circulating biomarkers.
TIF from renal cell carcinoma and adjacent normal
kidneys was compared by MS, and 138 differentially
regulated proteins were identified. Enolase 2 and
thrombospondin-1 were found to be upregulated in the
sera of renal cell carcinoma patients [88]. Proteomic
analysis of sera from mice implanted with orthotopic hu-
man oral squamous cell carcinomas allowed discrimin-
ation between host- and tumor-derived proteins.
Furthermore, 31 murine proteins were identified as dif-
ferentially regulated, including α-2-HS-glycoprotein,
complement C3 and C4 and hemopexin [89]. Circulating
proteolytic peptides cleaved by carboxypeptidase N in
the tumor microenvironment have been shown to have
potential for early detection of breast cancer [90]. Inte-
grated analysis of tumor cell line secretome and plasma
has provided a means for identifying potential circulat-
ing markers. A study that targeted glycoproteins se-
creted from the human colon carcinoma cell line
LIM1215 as a source of potential colorectal carcinoma
biomarkers identified a set of glycoproteins that were
also found in tumor xenograft TIF and in plasma derived
from mice bearing the LIM1215 xenograft tumor [91].
Although host- and microenvironment-derived pro-
teins may well serve as cancer biomarkers, there is a
considerable challenge in confirming their specificity for
particular tumor types or stages of tumor development,
and more broadly their cancer specificity. On the other
hand, studies to date suggest that detecting signatures in
plasma derived from the tumor microenvironment
might provide the necessary sensitivity to determine the
presence of tumors at an early stage. Thus, there is likely
to be a trade-off between sensitivity and specificity in
the use of microenvironment-derived markers for the
early detection of tumors.
Conclusions
The interactions between tumor cells and surrounding
tissue represent a crucial area of study in the elucidation
of mechanisms of cancer development, progression and
metastasis, and in providing novel avenues for cancer
detection and treatment. Proteomics is particularly well
suited for the analysis of the microenvironment, given
the host origin of numerous components of the micro-
environment that lack discernible genomic alterations,
and given the contribution of protein release and shed-
ding of proteins from the surface of cancer cells that
cannot be predicted strictly from genomic analysis.Proteomic analysis in particular has enhanced under-
standing of how tumor cells modify their microenviron-
ment through production of ECM structural proteins,
ECM-modifying proteins and proteases. Proteomics has
further enhanced the global identification of protease
targets. Combining MS or antibody arrays with experi-
mental approaches, such as co-culture of cancer cells
with tumor-associated fibroblasts, has also facilitated the
identification of growth and signaling factors produced
by stromal and infiltrating cells.
Early use of proteomics in cancer research primarily
focused on the identification or quantification of pro-
teins, and provided only modest insight into the bio-
logical relevance of the findings. As proteomic
technologies become more widely utilized, targeted ap-
proaches should be applied to elucidate the function of
particular proteins. Likewise, as MS technology improves
through increased scanning speeds and more sensitive
instruments, a larger number of identified proteins and
smaller perturbations of protein abundance, along with
post-translational modifications, will be observed, allow-
ing for a more fully informative readout of protein ex-
pression. Moreover, given that a large fraction of the
proteome has an enzymatic function, assessment of ac-
tivity states, cleavage products and metabolic intermedi-
ates will be needed to appreciate more fully the dynamic
nature of the tumor microenvironment and key targets
for intervention.
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